BMY Bristol Myers SquibbcompanySEC Filings & Insider Trading Activity 2026
Latest Bristol Myers Squibb (BMY) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 11, 2026, a 10-Q quarterly report filed on October 30, 2025, an 8-K current report filed on April 30, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Bristol Myers Squibb (BMY) (SEC CIK 14272), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model focused on oral immunomodulatory and oncology drugs, primarily treating multiple myeloma and CML
- • FDA-approved volume-unlimited generics launched for Revlimid (2026), pomalidomide generics entering U.S. (Mar 2026), dasatinib generics active since Sept 2024
Risk Factors
- • FDA approval of Breyanzi in Dec 2025 for relapsed/refractory MZL after ≥2 systemic therapies, impacting market access and revenue
- • Exposure to Japan's approval landscape with multiple key drug approvals by Ministry of Health Labour and Welfare in 2025, critical for Asia Pacific growth
Management Discussion & Analysis
- • Revenue and YoY change: Not disclosed in provided section
- • Profitability or margin change: Not disclosed in provided section
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue details not explicitly provided in excerpt; focus on expense trends instead
- • Operating expenses $9.11B Q3 2025 vs $10.22B Q3 2024, down 11% YoY; YTD $27.83B vs $44.51B, down 37% YoY
Risk Factors
- • No newly added risk factors explicitly stated this quarter, focus on product approvals updates
- • Regulatory risk from accelerated approvals of Opdivo + Yervoy for multiple indications in Japan, EC, and FDA between Feb-Aug 2025
Annual Reports Archive10-K
AI-powered analysis of Bristol Myers Squibb (BMY) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Bristol Myers Squibb (BMY) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Profitability | |||||
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |
| Net Income | $7.0B | $6.3B | $8.0B | -$8.9B | $7.1B |
| Net Margin | 15.1% | 13.7% | 17.8% | -18.5% | 14.6% |
| Balance Sheet | |||||
| Total Assets | $109.3B | $96.8B | $95.2B | $92.6B | $90.0B |
| Equity | $35.9B | $31.1B | $29.4B | $16.3B | $18.5B |
| ROE | 19.5% | 20.4% | 27.3% | -54.8% | 38.2% |
Source: XBRL financial data from Bristol Myers Squibb (BMY) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 30, 2026 | — | — | — |
10-K | Feb 11, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 5, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Oct 30, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Jul 31, 2025 | Jun 30, 2025 | Analysis | |
10-Q | Apr 24, 2025 | Mar 31, 2025 | Analysis | |
10-K | Feb 12, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Jul 26, 2024 | Jun 30, 2024 | — | |
10-Q | Apr 25, 2024 | Mar 31, 2024 | — | |
10-K | Feb 13, 2024 | Dec 31, 2023 | — | |
10-Q | Oct 26, 2023 | Sep 30, 2023 | — | |
10-Q | Jul 27, 2023 | Jun 30, 2023 | — | |
10-Q | Apr 27, 2023 | Mar 31, 2023 | — | |
10-K | Feb 14, 2023 | Dec 31, 2022 | — | |
10-Q | Oct 26, 2022 | Sep 30, 2022 | — | |
10-Q | Jul 27, 2022 | Jun 30, 2022 | — | |
10-Q | Apr 29, 2022 | Mar 31, 2022 | — | |
10-K | Feb 9, 2022 | Dec 31, 2021 | — | |
10-Q | Oct 27, 2021 | Sep 30, 2021 | — | |
10-Q | Jul 28, 2021 | Jun 30, 2021 | — | |
10-Q | Apr 29, 2021 | Mar 31, 2021 | — | |
10-K | Feb 10, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 5, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest BMY SEC filings in 2026?
Bristol Myers Squibb (BMY) has filed a 10-K annual report on February 11, 2026, a 10-Q quarterly report on October 30, 2025, an 8-K current report on April 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did BMY file its most recent 10-K annual report?
Bristol Myers Squibb (BMY) filed its most recent 10-K annual report on February 11, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view BMY 10-Q quarterly reports?
Bristol Myers Squibb (BMY)'s most recent 10-Q quarterly report was filed on October 30, 2025. SignalX displays every BMY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has BMY filed recently?
Bristol Myers Squibb (BMY)'s most recent 8-K was filed on April 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find BMY insider trading activity (Form 4)?
SignalX aggregates every BMY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does BMY file with the SEC?
Bristol Myers Squibb (BMY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BMY filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Bristol Myers Squibb (BMY).
What is BMY's SEC CIK number?
Bristol Myers Squibb (BMY)'s SEC CIK (Central Index Key) number is 14272. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 14272 to look up all BMY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find BMY return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Bristol Myers Squibb (BMY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Bristol Myers Squibb SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 32+ filings.